Psoriasis and vascular risk: An update

Current Pharmaceutical Design

Volumn 20, Issue 39, 2014, Pages 6114-6125

  Katsiki, Niki ^a   Anagnostis, Panagiotis ^a,b   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b Division of Endocrinology Police Medical Center of Northern Greece   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Metabolic syndrome; Non alcoholic fatty liver disease; Psoriasis; Psoriatic arthritis; Vascular risk factors

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIPSORIASIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METHOTREXATE; PIOGLITAZONE; RETINOID; TUMOR NECROSIS FACTOR INHIBITOR; URIC ACID;

ABDOMINAL AORTA ANEURYSM; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; SMOKING; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION; COMPLICATION; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; PSORIASIS; RISK FACTORS;

EID: 84911488876     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140417105323     Document Type: Article

References (277)

1. Pietrzak A, Bartosińska J, Chodorowska G, Szepietowski JC, Paluszkiewicz P, Schwartz RA. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol 2013; 52: 153-62.
2. Doukaki S, Caputo V, Bongiorno MR. Psoriasis and Cardiovascular Risk: Assessment by CUORE Project Risk Score in Italian Patients. Dermatol Res Pract 2013; 2013: 389031.
3. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-7.
4. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics Other Than the Diagnostic Criteria Associated with Metabolic Syndrome: an Overview. Curr Vasc Pharmacol 2013 Apr 25. [Epub ahead of print].
5. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hyperuri-caemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698-705.
6. Kostapanos MS, Mikhailidis DP, Elisaf MS, Steiropoulos P, Papanas N. Obstructive sleep apnoea syndrome and cardiovascular risk. Arch Med Sci 2012; 8: 1115-6.
7. Liapis CD, Bell PF, Mikhailidis DP, et al; ESVS Guidlines Collaborators; European Society for Vascular Surgery. ESVS Guidelines: Section B-diagnosis and investigation of patients with carotid stenosis. Curr Vasc Pharmacol 2010; 8: 682-91.
8. Paraskevas KI, Kotsikoris I, Koupidis SA, Giannoukas AD, Mikhailidis DP. Ankle--brachial index: a marker of both peripheral arterial disease and systemic atherosclerosis as well as a predictor of vascular events. Angiology 2010; 61: 521-3.
9. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011; 5: 24-34.
10. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Stage of chronic kidney disease and severity of coronary heart disease manifestation. Expert Opin Pharmacother 2012; 13: 457-60.
11. Raychaudhuri SP. Comorbidities of psoriatic arthritis--metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012; 39: 437-40.
12. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20: 416-22.
13. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009; 35: 313-24.
14. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and metaanalysis of observational studies. J Hypertens 2013; 31: 433-42.
15. Bacaksiz A, Erdogan E, Sonmez O, et al. Ambulatory blood pressure monitoring can unmask hypertension in patients with psoriasis vulgaris. Med Sci Monit 2013; 19: 501-9.
16. Bacaksiz A, Akif Vatankulu M, Sonmez O, et al. Non-dipping nocturnal blood pressure in psoriasis vulgaris. Wien Klin Wo-chenschr 2012; 124: 822-9.
17. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 2008; 126: 302-12.
18. Markuszeski L, Bissinger A, Janusz I, Narbutt J, Jedrzejowska AS, Zalewska A. Heart rate and arrhythmia in patients with psoriasis vulgaris. Arch Med Res 2007; 38: 64-9.
19. Sarli B, Dogan Y, Baktir AO, et al. Heart rate recovery is impaired in patients with psoriasis. Med Princ Pract 2013; 22: 567-70.
20. Gaydukova I, Rebrov A, Nikitina N, Poddubnyy D. Decreased heart rate variability in patients with psoriatic arthritis. Clin Rheumatol 2012; 31: 1377-81.
21. Holman AJ, Ng E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. Auton Neu-rosci 2008; 143: 58-67.
22. Vena GA, Altomare G, Ayala F, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol 2010; 20: 593-8.
23. Lamba G, Palaniswamy C, Singh T, et al. Psoriasis induced by losartan therapy: a case report and review of the literature. Am J Ther 2011; 18: e78-80.
24. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010; 49: 1351-61.
25. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606-15.
26. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 2013; 168: 86-95.
27. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol 2008; 88: 561-5.
28. Goldenstein-Schainberg C, Favarato MH, Ranza R. Current and relevant concepts in psoriatic arthritis. Rev Bras Reumatol 2012; 52: 98-106.
29. Ramonda R, Lo Nigro A, Modesti V, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011; 10: 773-8.
30. Ma C, Schupp CW, Armstrong EJ, Armstrong AW. Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES). J Eur Acad Dermatol Venereol 2013 Aug 1. doi: 10. 1111/jdv. 12232. [Epub ahead of print].
31. Miller IM, Skaaby T, Ellervik C, Jemec GB. Quantifying Cardiovascular Disease Risk Factors in Psoriasis patients-a Metaanalysis. Br J Dermatol 2013 Jul 1. doi: 10. 1111/bjd. 12490. [Epub ahead of print].
32. Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012; 224: 218-21.
33. Holzer M, Wolf P, Curcic S, et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 2012; 53: 1618-24.
34. Yu Y, Sheth N, Krishnamoorthy P, et al. Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis 2012; 2: 285-92.
35. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000; 59: 904-9.
36. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5: 928-48.
37. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
38. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-2.
39. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
40. Saraceno R, Rizza S, Faleri S, et al. High density cholesterol level as predictor of clinical response to anti-TNF-alpha therapy in psoriatic patients. J Biol Regul Homeost Agents 2013; 27: 903-8.
41. Akkara Veetil BM, Matteson EL, Maradit-Kremers H, McEvoy MT, Crowson CS. Trends in lipid profiles in patients with psoriasis: a population-based analysis. BMC Dermatol 2012; 12: 20.
42. Holzer M, Wolf P, Inziner M, et al. Anti-Psoriatic Therapy Recovers High-Density Lipoprotein Composition and Function. J Invest Dermatol 2013 Aug 28. doi: 10. 1038/jid. 2013. 359. [Epub ahead of print].
43. Castro KR, Aikawa NE, Saad CG, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol 2011; 2011: 352686.
44. Athyros VG, Katsiki N, Tziomalos K, et al; GREACE Study Collaborative Group. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci 2013; 9: 418-26.
45. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: an Update. Curr Pharm Des 2013 Sep 12. [Epub ahead of print].
46. Athyros VG, Ganotakis E, Kolovou GD, et al; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; 9: 647-57.
47. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins and non-alcoholic fatty liver disease: a bright future? Expert Opin In-vestig Drugs 2013; 22: 1089-93.
48. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins 'IDEAL' for non-alcoholic fatty liver disease? Curr Med Res Opin 2013 Oct 28. [Epub ahead of print].
49. Nikolic D, Nikfar S, Salari P, et al; Lipid and Blood Pressure MetaAnalysis Collaboration Group. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013; 29: 435-51.
50. Paraskevas KI, Mikhailidis DP, Giannoukas AD. Statins: A sine qua non of the management of patients with abdominal aortic aneurysms. Int J Cardiol 2013; 168: 4528.
51. Mikhailidis DP. Lipids and non-cardiac vascular disease: a lecture overview. Curr Vasc Pharmacol 2012; 10: 743-4.
52. Paraskevas KI, Wierzbicki AS, Mikhailidis DP. Statins and noncardiac vascular disease. Curr Opin Cardiol 2012; 27: 392-7.
53. Liapis CD, Bell PR, Mikhailidis D, et al; ESVS Guidelines Collaborators. ESVS guidelines. Invasive treatment for carotid stenosis: indications, techniques. Eur J Vasc Endovasc Surg 2009; 37: 1-19.
54. Mosiewicz J, Pietrzak A, Chodorowska G, et al. Rational for statin use in psoriatic patients. Arch Dermatol Res 2013; 305: 467-72.
55. Ghazizadeh R, Tosa M, Ghazizadeh M. Clinical improvement in psoriasis with treatment of associated hyperlipidemia. Am J Med Sci 2011; 341: 394-8.
56. Brauchli YB, Jick SS, Meier CR. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol 2011; 65: 77-83.
57. Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Rezaei Hemami M. Atorvastatin for the treatment of plaque-type psoriasis. Pharmacotherapy 2011; 31: 1045-50.
58. Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol 1988; 124: 854-5.
59. Nemati H, Khodarahmi R, Rahmani A, Ebrahimi A, Amani M, Eftekhari K. Serum lipid profile in psoriatic patients: correlation between vascular adhesion protein 1 and lipoprotein (a). Cell Bio-chem Funct 2013; 31: 36-40.
60. Ferretti G, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol 2012; 166: 204-7.
61. Pietrzak A, Kadzielewski J, Janowski K, et al. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int J Dermatol 2009; 48: 379-87.
62. Coimbra S, Oliveira H, Reis F, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol 2010; 11: 423-32.
63. Tobin AM, Ahern T, Rogers S, Collins P, O'Shea D, Kirby B. The dermatological consequences of obesity. Int J Dermatol 2013; 52: 927-32.
64. Herédi E, Csordás A, Clemens M, et al. The prevalence of obesity is increased in patients with late compared with early onset psoriasis. Ann Epidemiol 2013; 23: 688-92.
65. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and metaanalysis of observational studies. Nutr Diabetes 2012; 2: e54.
66. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012; 71: 1273-7.
67. Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010; 146: 721-6.
68. Labitigan M, Bahce-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013 Oct 7. doi: 10. 1002/acr. 22185. [Epub ahead of print].
69. Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and Psoriasis: Inflammatory Nature of Obesity, Relationship Between Psoriasis and Obesity, and Therapeutic Implications. Actas Dermosifiliogr 2012 Nov 23. [Epub ahead of print].
70. Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013; 52: 62-7.
71. Paspala I, Katsiki N, Kapoukranidou D, Mikhailidis DP, Tsiligi-roglou-Fachantidou A. The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity. Open Car-diovasc Med J 2012; 6: 147-55.
72. Katsiki N, Yovos JG, Gotzamani-Psarrakou A, Karamitsos DT. Adipokines and vascular risk in type 2 diabetes mellitus. Angiology 2011; 62: 601-4.
73. di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013; 65: 141-7.
74. Kim GE, Seidler E, Kimball AB. The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. J Eur Acad Dermatol Venereol 2013 Jan 24. doi: 10. 1111/jdv. 12089. [Epub ahead of print].
75. Carrascosa JM, Vilavella M, Garcia-Doval I, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2013 Jul 15. doi: 10. 1111/jdv. 12208. [Epub ahead of print].
76. Roongpisuthipong W, Pongpudpunth M, Roongpisuthipong C, Rajatanavin N. The effect of weight loss in obese patients with chronic stable plaque-type psoriasis. Dermatol Res Pract 2013; 2013: 795932.
77. Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 2013; 149: 795-801.
78. Farias MM, Achurra P, Boza C, Vega A, de la Cruz C. Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. Obes Surg 2012; 22: 877-80.
79. Faurschou A, Zachariae C, Skov L, Vilsbøll T, Knop FK. Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism? Med Hypotheses 2011; 77: 1098-101.
80. Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol 2013; 27: e186-90.
81. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and Smoking: A Systematic Review and Meta-Analysis. Br J Dermatol 2013 Oct 11. doi: 10. 1111/bjd. 12670. [Epub ahead of print].
82. Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 2012; 175: 402-13.
83. Emre S, Metin A, Demirseren DD, Kilic S, Isikoglu S, Erel O. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2012 Sep 25. doi: 10. 1111/j. 1468-3083. 2012. 04700. x. [Epub ahead of print].
84. Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 2011; 165: 1162-8.
85. Morita A. Tobacco smoke causes premature skin aging. J Dermatol Sci 2007; 48: 169-75.
86. Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012; 71: 804-8.
87. Eder L, Shanmugarajah S, Thavaneswaran A, et al. The association between smoking and the development of psoriatic arthritis among psoriasis patients. Ann Rheum Dis 2012; 71: 219-24.
88. Tillett W, Jadon D, Shaddick G, et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 2013; 72: 1358-61.
89. Eder L, Law T, Chandran V, et al. Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. Arthritis Care Res (Hoboken) 2011; 63: 1091-7.
90. Elahmed HH. Rapid improvement of palmoplantar psoriasis after cessation of smoking. Sultan Qaboos Univ Med J 2013; 13: 188-9.
91. Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol 2013; 14: 1-7.
92. Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician 2012; 58: 404-8.
93. Gómez-Fernández C, Herranz Pinto P, Casado Verrier B, Senda-gorta Cudós E, Beato-Merino MJ, Jiménez MC. Drug eruption and exacerbation of psoriasis related to bupropion. Eur J Dermatol 2011; 21: 120-1.
94. Brenaut E, Horreau C, Pouplard C, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27: 30-5.
95. Zhu KJ, Zhu CY, Fan YM. Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J Dermatol 2012; 39: 770-3.
96. Farkas A, Kemény L. Alcohol, liver, systemic inflammation and skin: a focus on patients with psoriasis. Skin Pharmacol Physiol 2013; 26: 119-26.
97. Athyros VG, Liberopoulos EN, Mikhailidis DP, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiol-ogy 2007; 58: 689-97.
98. Movva R, Figueredo VM. Alcohol and the heart: To abstain or not to abstain? Int J Cardiol 2013; 164: 267-76.
99. Vasanthi HR, Parameswari RP, DeLeiris J, Das DK. Health benefits of wine and alcohol from neuroprotection to heart health. Front Biosci (Elite Ed) 2012; 4: 1505-12.
100. Kolovou GD, Salpea KD, Anagnostopoulou KK, Mikhailidis DP. Alcohol use, vascular disease, and lipid-lowering drugs. J Pharmacol Exp Ther 2006; 318: 1-7.
101. Hansel B, Kontush A, Bruckert E. Is a cardioprotective action of alcohol a myth? Curr Opin Cardiol 2012; 27: 550-5.
102. Mikhailidis DP, Katsiki N, Athyros VG, Karagiannis A. Alcohol consumption and the heart. Int J Cardiol 2013; 168: 4319.
103. Miyamae M, Kaneda K, Domae N, Figueredo VM. Cardioprotec-tion by regular ethanol consumption: potential mechanisms and clinical application. Curr Drug Abuse Rev 2010; 3: 39-48.
104. Qureshi AA, Dominguez PL, Choi HK, Han J, Curhan G. Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol 2010; 146: 1364-9.
105. Vena GA, Cassano N. The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs. Expert Opin Drug Metab Toxicol 2012; 8: 959-72.
106. Pietrzak A, Jastrzçbska I, Chodorowska G, et al. Psoriasis and unreported excessive alcohol intake--a simple screening approach. J Eur Acad Dermatol Venereol 2011; 25: 1261-8.
107. McAleer MA, Mason DL, Cunningham S, et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol 2011; 164: 1256-61.
108. Gerkowicz A, Pietrzak A, Szepietowski JC, Radej S, Chodorowska G. Biochemical markers of psoriasis as a metabolic disease. Folia Histochem Cytobiol 2012; 50: 155-70.
109. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2013; 169: 266-82.
110. Chandran V. Soluble biomarkers may differentiate psoriasis from psoriatic arthritis. J Rheumatol Suppl 2012; 89: 65-6.
111. Fitzgerald O, Chandran V. Update on biomarkers in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012; 39: 427-30.
112. Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol 2013 Sep 3. doi: 10. 1111/jdv. 12257. [Epub ahead of print].
113. Romaní J, Caixàs A, Carrascosa JM, Ribera M, Rigla M, Luelmo J. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol 2012; 166: 1237-44.
114. Montaudié H, Albert-Sabonnadière C, Acquacalda E, et al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2013 Aug 24. doi: 10. 1111/jdv. 12255. [Epub ahead of print].
115. Ramonda R, Modesti V, Ortolan A, et al. Serological markers in psoriatic arthritis: promising tools. Exp Biol Med (Maywood) 2013 Oct 21. [Epub ahead of print].
116. Wagner CL, Visvanathan S, Elashoff M, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis 2013; 72: 83-8.
117. Coimbra S, Oliveira H, Figueiredo A, Rocha-Pereira P, Santos-Silva A. Factors associated with the length of remission of psoriasis vulgaris. Clin Drug Investig 2013; 33: 855-60.
118. Vayá A, Ricart JM, Andino B, Todoli J, Nuñez C, Calvo J, Bautista D. Psoriasis and hemorheology. Influence of the metabolic syndrome. Clin Hemorheol Microcirc 2012 Oct 22. [Epub ahead of print].
119. Nielsen HJ, Christensen IJ, Svendsen MN, et al. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. In-flamm Res 2002; 51: 563-7.
120. Saleh HM, Attia EA, Onsy AM, Saad AA, Abd Ellah MM. Platelet activation: a link between psoriasis per se and subclinical athero-sclerosis--a case-control study. Br J Dermatol 2013; 169: 68-75.
121. Marongiu F, Sorano GG, Bibbò C, et al. Abnormalities of blood coagulation and fibrinolysis in psoriasis. Dermatology 1994; 189: 32-7.
122. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol 2012; 39: 334-6.
123. Canpolat F, Akpinar H, Eskioglu F. Mean platelet volume in psoriasis and psoriatic arthritis. Clin Rheumatol 2010; 29: 325-8.
124. Pamuk GE, Nuri Pamuk O, Orüm H, Arican O, Turgut B, Demir M. Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009; 20: 493-7.
125. Garbaraviciene J, Diehl S, Varwig D, et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol 2010; 19: 736-41.
126. Chen M, Holland MJ, Mir MR, et al. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors. J Drugs Dermatol 2011; 10: 280-4.
127. Brunasso AM, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. J Am Acad Dermatol 2009; 60: 781-5.
128. Davidovici BB, Sullivan-Whalen MM, Gilleaudeau P, Krueger JG. Differing effect of systemic anti psoriasis therapies on platelet physiology--a case report and review of literature. BMC Dermatol 2010; 10: 2.
129. Laurent S, Briet M, Boutouyrie P. Arterial stiffness as surrogate end point: needed clinical trials. Hypertension 2012; 60: 518-22.
130. Koumaras C, Tzimou M, Stavrinou E, et al. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs 2012; 12: 143-56.
131. Katsiki N, Gkaliagkousi E, Karagiannis A, Mikhailidis DP. Treating arterial stiffness in metabolic syndrome and type 2 diabetes mellitus. Open J Hypertens 2013; 5: In press.
132. Seifalian AM, Filippatos TD, Joshi J, Mikhailidis DP. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010; 8: 155-68.
133. Athyros VG, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin 2013; 29: 1263-74.
134. Doonan RJ, Hausvater A, Scallan C, Mikhailidis DP, Pilote L, Daskalopoulou SS. The effect of smoking on arterial stiffness. Hy-pertens Res 2010; 33: 398-410.
135. Balta I, Balta S, Demirkol S, et al. Aortic Arterial Stiffness is a Moderate Predictor of Cardiovascular Disease in Patients With Psoriasis Vulgaris. Angiology 2013 May 1. [Epub ahead of print].
136. Yiu KH, Yeung CK, Chan HT, et al. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2011; 164: 514-20.
137. Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol Ther 2010; 23: 144-51.
138. Bicer A, Acikel S, Kilic H, et al. Impaired aortic elasticity in patients with psoriasis. Acta Cardiol 2009; 64: 597-602.
139. Sen BB, Erayman A, Sen N. Is Arterial Stiffness a Predictor of Cardiovascular Disease in All Patients With Psoriasis? Angiology 2013 Sep 3. [Epub ahead of print].
140. Aydin E, Karabacak E, Altun B, Dinc M, Kutlu A. Arterial Stiffness Without Other Inflammatory Markers May Not Accurately Provide Information to Clinicians About the Severity of Psoriasis. Angiology 2013 Jun 20. [Epub ahead of print].
141. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 2009; 218: 110-3.
142. Costa L, Caso F, D'Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 2012; 31: 711-5.
143. Jamnitski A, Symmons D, Peters MJ, Sattar N, Mclnnes I, Nurmo-hamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72: 211-6.
144. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens 2012; 25: 644-50.
145. De Simone C, Di Giorgio A, Sisto T, Carbone A, Ghitti F, Tondi P, Santoliquido A. Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. Eur J Dermatol 2011; 21: 510-4.
146. Martínez-Sales V, Vila V, Ricart JM, et al. Increased circulating endothelial cells and microparticles in patients with psoriasis. Clin Hemorheol Microcirc 2013 Sep 3. [Epub ahead of print].
147. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 287-93.
148. Nofal A, Al-Makhzangy I, Attwa E, Nassar A, Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol 2009; 23: 803-6.
149. Fink AM, Cauza E, Hassfeld W, et al. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007; 25: 305-8.
150. Butt C, Lim S, Greenwood C, Rahman P. VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Muscu-loskelet Disord. 2007; 8: 1.
151. Simonetti O, Lucarini G, Goteri G, et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J Immunopathol Pharmacol 2006; 19: 751-60.
152. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endo-can in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013; 169: 1066-70.
153. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, et al. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol 2011; 164: 26-32.
154. Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW. Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review. Curr Pharm Des 2013 Apr 2. [Epub ahead of print].
155. Crawshaw AA, Griffiths CE, Young HS. Investigational VEGF antagonists for psoriasis. Expert Opin Investig Drugs 2012; 21: 33-43.
156. Weidemann AK, Crawshaw AA, Byrne E, Young HS. Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis. Clin Cosmet Investig Dermatol 2013; 6: 233-44.
157. Brazzelli V, Grasso V, Fornara L, et al. Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. Int J Immunopathol Pharmacol 2010; 23: 911-6.
158. McDonald I, Connolly M, Tobin AM. A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab 2012; 2012: 965385.
159. Tobin AM, Veale DJ, Fitzgerald O, et al. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37: 1386-94.
160. Richetta AG, Mattozzi C, Macaluso L, et al. Homocysteine plasmatic status in patients with psoriasis. Eur J Dermatol 2011; 21: 621-3.
161. Juzeniene A, Stokke KT, Thune P, Moan J. Pilot study of folate status in healthy volunteers and in patients with psoriasis before and after UV exposure. J Photochem Photobiol B 2010; 101: 111-6.
162. Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011; 25: 12-8.
163. Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007; 56: 831-9.
164. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 2009; 20: 197-207.
165. Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des 2010; 16: 3417-34.
166. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Vitamin D deficiency, statin-related myopathy and other links with vascular risk. Curr Med Res Opin 2011; 27: 1691-2.
167. Touma Z, Eder L, Zisman D, et al. Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care Res (Hoboken) 2011; 63: 1440-7.
168. Gisondi P, Rossini M, Di Cesare A, et al. Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol 2012; 166: 505-10.
169. Ahn CS, Awadalla F, Huang KE, Yentzer B, Dabade TS, Feldman SR. Patterns of vitamin d analog use for the treatment of psoriasis. J Drugs Dermatol 2013; 12: 906-10.
170. Mason A, Mason J, Cork M, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis: An abridged Cochrane Systematic Review. J Am Acad Dermatol 2013; 69: 799-807.
171. Bailey EE, Ference EH, Alikhan A, Hession MT, Armstrong AW. Combination treatments for psoriasis: a systematic review and meta-analysis. Arch Dermatol 2012; 148: 511-22.
172. Campione E, Mazzotta A, Paternò EJ, Diluvio L, Prinz JC, Chi-menti S. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. Acta Derm Venereol 2009; 89: 288-91.
173. Kamangar F, Koo J, Heller M, Lee E, Bhutani T. Oral vitamin D, still a viable treatment option for psoriasis. J Dermatolog Treat 2013; 24: 261-7.
174. Gaál J, Lakos G, Szodoray P, et al. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: results of an open, follow-up pilot study. Acta Derm Venereol 2009; 89: 140-4.
175. Fu LW, Vender R. Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome. Dermatol Res Pract 2011; 2011: 276079.
176. Juzeniene A, Moan J. Beneficial effects of UV radiation other than via vitamin D production. Dermatoendocrinol 2012; 4: 109-17.
177. Kostapanos MS, Elisaf MS, Mikhailidis DP. Obstructive sleep apnea and cardiovascular risk: is metabolic syndrome the link? An-giology 2012; 63: 569-73.
178. Karaca S, Fidan F, Erkan F, et al. Might psoriasis be a risk factor for obstructive sleep apnea syndrome? Sleep Breath 2013; 17: 275-80.
179. Yang YW, Kang JH, Lin HC. Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. Sleep Med 2012; 13: 285-9.
180. Gowda S, Goldblum OM, McCall WV, Feldman SR. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol 2010; 63: 114-23.
181. Maari C, Bolduc C, Nigen S, Marchessault P, Bissonnette R. Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial. J Derma-tolog Treat 2012 Sep 19. [Epub ahead of print].
182. Levesque A, Lachaine J, Bissonnette R. Risk of myocardial infarction in canadian patients with psoriasis: a retrospective cohort study. J Cutan Med Surg 2013; 17: 398-403.
183. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009; 68: 1131-5.
184. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149: 1173-9.
185. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-6.
186. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and metaanalysis of observational studies. J Am Heart Assoc 2013; 2: e000062.
187. Sunbul M, Agirbasli M. Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk? Curr Pharm Des 2013 Apr 2. [Epub ahead of print].
188. Gullu H, Caliskan M, Dursun R, Ciftci O, Guven A, Muderrisoglu H. Impaired coronary microvascular function and its association with disease duration and inflammation in patients with psoriasis. Echocardiography 2013; 30: 912-8.
189. Armstrong AW, Harskamp CT, Ledo L, Rogers JH, Armstrong EJ. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol 2012; 109: 976-80.
190. Ahlehoff O, Lindhardsen J, Gislason GH, et al. Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries. BMC Cardiovasc Disord 2012; 12: 79.
191. Rajpara AN, Goldner R, Gaspari A. Psoriasis: can statins play a dual role? Dermatol Online J 2010; 16: 2.
192. Wu JJ, Poon KT, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148: 1244-50.
193. Wu JJ, Poon KY, Bebchuk JD. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. J Drugs Dermatol 2013; 12: 899-903.
194. Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27: 12-29.
195. Xu XC, Feng AP. Characteristics of patients with psoriasis and Type 2 diabetes in a central China case-control study. Eur J Dermatol 2012; 22: 396-7.
196. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-6.
197. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-7.
198. Li W, Han J, Hu FB, Curhan GC, Qureshi AA. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol 2012; 132: 291-8.
199. Ahlehoff O, Gislason GH, Jørgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012; 33: 2054-64.
200. Armstrong AW, Azizi S, Wu J, et al. Psoriasis, electrocardiographic characteristics, and incidence of atrial fibrillation. Arch Dermatol Res 2013; 305: 891-7.
201. Kupetsky EA, Rincon F. The Prevalence of Systemic Diseases Associated with Dermatoses and Stroke in the United States: A Cross-Sectional Study. Dermatology 2013 Nov 12. [Epub ahead of print].
202. Ramagopalan SV, Pakpoor J, Seminog O, Goldacre R, Graham L, Goldacre MJ. Risk of subarachnoid haemorrhage in people admitted to hospital with selected immune-mediated diseases: record-linkage studies. BMC Neurol 2013; 13: 176.
203. Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for im-mune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol. 2012; 12: 41.
204. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273: 197-204.
205. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA2011; 306: 864-71.
206. Reich K, Papp KA, Griffiths CE, et al; PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11: 300-12.
207. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; (1): CD007893.
208. Enany B, El Zohiery AK, Elhilaly R, Badr T. Carotid intima-media thickness and serum leptin in psoriasis. Herz 2012; 37: 527-33.
209. Tam LS, Shang Q, Li EK, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008; 59: 1322-31.
210. Lin YC, Dalal D, Churton S, et al. Relationship between metabolic syndrome and carotid intima media thickness: Cross-sectional comparison between psoriasis and psoriatic arthritis. Arthritis Care Res (Hoboken) 2013 Aug 27. doi: 10. 1002/acr. 22144. [Epub ahead of print].
211. Eder L, Jayakar J, Shanmugarajah S, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis 2013; 72: 715-20.
212. Eder L, Chandran V, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis 2013 Jul 25. doi: 10. 1136/annrheumdis-2013-203433. [Epub ahead of print].
213. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G; CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol 2011; 31: 705-12.
214. Di Minno MN, Peluso R, Iervolino S, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study. Arthritis Res Ther 2012; 14: R211.
215. Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med 2011; 26: 1036-49.
216. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Feder-man DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-3.
217. Puig L. Cardiovascular risk and psoriasis: the role of biologic therapy. Actas Dermosifiliogr 2012; 103: 853-62.
218. Hur DJ, Kizilgul M, Aung WW, Roussillon KC, Keeley EC. Frequency of coronary artery disease in patients undergoing peripheral artery disease surgery. Am J Cardiol 2012; 110: 736-40.
219. Sirico G, Spadera L, De Laurentis M, Brevetti G. Carotid artery disease and stroke in patients with peripheral arterial disease. The role of inflammation. Monaldi Arch Chest Dis 2009; 72: 10-7.
220. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg 2009; 23: 690-9.
221. Vlachopoulos C, Terentes-Printzios D, Stefanadis C. How to identify subjects with poly-vascular disease? Curr Vasc Pharmacol 2012; 10: 728-30.
222. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ 2013; 347: f5961.
223. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gel-fand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U. K. Br J Dermatol 2010; 163: 586-92.
224. Akoglu H, Dede F, Akoglu G, Gonul II, Odabas AR. Membra-noproliferative glomerulonephritis associated with psoriasis vulgaris. Ren Fail 2009; 31: 858-61.
225. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB; National Psoriasis Foundation. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010; 62: 838-53.
226. Boey O, Van Hooland S, Woestenburg A, Van der Niepen P, Ver-beelen D. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg 2006; 61: 166-9.
227. Saougou I, Papagoras C, Markatseli TE, Voulgari PV, Drosos AA. A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review. Clin Rheumatol 2010; 29: 1455-9.
228. Dubreuil M, Rho YH, Man A, et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 2013 Oct 31. [Epub ahead of print].
229. Coto-Segura P, Eiris-Salvado N, González-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol 2013; 169: 783-93.
230. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 84-91.
231. Dreiher J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract 2013; 2013: 580404.
232. Armesto S, Santos-Juanes J, Galache-Osuna C, Martinez-Camblor P, Coto E, Coto-Segura P. Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population. Australas J Dermatol 2012; 53: 128-30.
233. Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol 2013; 27: 1329-35.
234. Glossmann H, Reider N. A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. Dermatoendocrinol 2013; 5: 252-63.
235. Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thia-zolidinediones for plaque psoriasis: a systematic review and metaanalysis. Evid Based Med 2012; 17: 171-6.
236. Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology 2012; 224: 20-1.
237. Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabe-tologia 2011; 54: 2741-4.
238. Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab 2012; 38: 86-8.
239. Moore AF, Soper T, Jones N, Grevelink J, Abourizk N. Psoriatic exacerbation associated with insulin therapy. Diabetes Care 2008; 31: e31.
240. Wang P, Ran Y. Subcutaneous injection of isophane protamine biosynthetic human insulin induced psoriasis at the injection site. Eur J Dermatol 2011; 21: 807-8.
241. Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006; 154: 83-6.
242. Russo GT, Minutoli L, Bitto A, et al. Methotrexate Increases Skeletal Muscle GLUT4 Expression and Improves Metabolic Control in Experimental Diabetes. J Nutr Metab 2012; 2012: 132056.
243. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schnee-weiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-31.
244. Wu JJ, Tsai TF. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol 2008; 144: 1403-4.
245. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2012; 39: 212-8.
246. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147: 419-24.
247. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013; 69: 1014-24.
248. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132: 556-62.
249. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-62.
250. Pehlevan S, Yetkin DO, Bahadir C, et al. Increased Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis. Metab Syndr Relat Disord 2013 Nov 8. [Epub ahead of print].
251. Torres T, Selores M. Does treatment of metabolic syndrome components improve psoriasis? Report of three cases. Eur J Dermatol 2012; 22: 270-2.
252. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
253. Athyros VG, Karagiannis A, Ganotakis ES, et al; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-68.
254. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl 2012; 89: 24-8.
255. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2013 Aug 20. [Epub ahead of print].
256. Piérard GE, Piérard-Franchimont C, Szepetiuk G, Paquet P, Quatresooz P. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther 2010; 10: 1197-208.
257. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008; 7: 563-72.
258. Madanagobalane S, Anandan S. The increased prevalence of nonalcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012; 53: 190-7.
259. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 2011; 25: 383-91.
260. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-64.
261. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-86.
262. Bishnoi P, Kumari R, Thappa DM. Monitoring methotrexate hepa-totoxicity in psoriasis. Indian J Dermatol Venereol Leprol 2011; 77: 545-8.
263. Campanati A, Ganzetti G, Di Sario A, et al. The effect of etaner-cept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48: 839-46.
264. Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol 2013; 28: 458-63.
265. Balci A, Celik M, Balci DD, et al. Patients with psoriasis have an increased amount of epicardial fat tissue. Clin Exp Dermatol 2013 Oct 25. [Epub ahead of print].
266. Bulbul Sen B, Atci N, Rifaioglu EN, et al. Increased epicardial fat tissue is a marker of subclinical atherosclerosis in patients with psoriasis. Br J Dermatol 2013; 169: 1081-6.
267. Akyildiz ZI, Seremet S, Emren V, et al. Epicardial Fat Thickness Is Independently Associated with Psoriasis. Dermatology 2013 Oct 18. [Epub ahead of print].
268. Gisondi P, Targher G, Cagalli A, Girolomoni G. Hyperuricemia in patients with chronic plaque psoriasis. J Am Acad Dermatol 2013 Oct 30. [Epub ahead of print].
269. Kwon HH, Kwon IH, Choi JW, Youn JI. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol 2011; 36: 473-8.
270. Cassano N, Carbonara M, Panaro M, Vestita M, Vena GA. Role of serum uric acid in conditioning the association of psoriasis with metabolic syndrome. Eur J Dermatol 2011; 21: 808-9.
271. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009; 39: 157-62.
272. Mazali FC, Johnson RJ, Mazzali M. Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. Nephron Exp Nephrol 2012; 120: e12-9.
273. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013; 27: 36-46.
274. Richard MA, Barnetche T, Horreau C, et al. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013; 27: 2-11.
275. Kamangar F, Neuhaus IM, Koo JY. An evidence-based review of skin cancer rates on biologic therapies. J Dermatolog Treat 2012; 23: 305-15.
276. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64: 1035-50.
277. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26: 22-31.